Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.

Lin YL, Liau JY, Yu SC, Ou DL, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL.

PLoS One. 2012;7(11):e50701. doi: 10.1371/journal.pone.0050701. Epub 2012 Nov 28.

PMID:
23209813
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.

Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S.

Anticancer Res. 2010 Jul;30(7):2531-8.

PMID:
20682979
[PubMed - indexed for MEDLINE]
3.

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.

J Natl Cancer Inst. 2011 Apr 20;103(8):674-88. doi: 10.1093/jnci/djr070. Epub 2011 Mar 11.

PMID:
21398618
[PubMed - indexed for MEDLINE]
Free Article
4.

Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.

Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P.

Anticancer Drugs. 2001 Oct;12(9):741-51.

PMID:
11593056
[PubMed - indexed for MEDLINE]
5.

Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.

Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC, Berger MR, Schad A, Weber A, Heeger S, Galle PR, Moehler M.

World J Gastroenterol. 2008 Jun 28;14(24):3829-40.

PMID:
18609706
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.

Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM.

Invest New Drugs. 2012 Dec;30(6):2219-25. doi: 10.1007/s10637-012-9793-y. Epub 2012 Jan 24.

PMID:
22270257
[PubMed - indexed for MEDLINE]
7.

Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.

Yeh KH, Cheng AL, Wan JP, Lin CS, Liu CC.

Anticancer Drugs. 2004 Apr;15(4):371-6.

PMID:
15057142
[PubMed - indexed for MEDLINE]
8.

MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.

Park JM, Huang S, Tougeron D, Sinicrope FA.

PLoS One. 2013 May 28;8(5):e65369. doi: 10.1371/journal.pone.0065369. Print 2013.

PMID:
23724141
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.

Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T.

Cancer Res. 2011 Mar 1;71(5):1520-5. doi: 10.1158/0008-5472.CAN-10-2817. Epub 2010 Dec 30.

PMID:
21193546
[PubMed - indexed for MEDLINE]
Free Article
10.

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.

Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J.

J Clin Oncol. 2013 Feb 20;31(6):759-65. doi: 10.1200/JCO.2012.45.1492. Epub 2012 Nov 26.

PMID:
23182985
[PubMed - indexed for MEDLINE]
Free Article
11.

MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.

Tentori L, Muzi A, Dorio AS, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.

Cancer Chemother Pharmacol. 2013 Jul;72(1):117-25. doi: 10.1007/s00280-013-2175-0. Epub 2013 May 1.

PMID:
23636450
[PubMed - indexed for MEDLINE]
12.

Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.

Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW.

Cancer Sci. 2013 Apr;104(4):473-80. doi: 10.1111/cas.12098. Epub 2013 Feb 14.

PMID:
23298313
[PubMed - indexed for MEDLINE]
13.

Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.

Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG.

Clin Cancer Res. 2004 Mar 15;10(6):2158-67.

PMID:
15041737
[PubMed - indexed for MEDLINE]
Free Article
14.

Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin.

van Huis-Tanja LH, Kweekel DM, Lu X, Franken K, Koopman M, Gelderblom H, Antonini NF, Punt CJ, Guchelaar HJ, van der Straaten T.

Mutat Res Fundam Mol Mech Mutagen. 2014 Jan;759:37-44. doi: 10.1016/j.mrfmmm.2013.11.001. Epub 2013 Nov 9.

PMID:
24220697
[PubMed - indexed for MEDLINE]
15.

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.

Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F.

Int J Cancer. 2014 May 1;134(9):2146-55.

PMID:
24136682
[PubMed - indexed for MEDLINE]
16.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J, Hancock DC.

Cell Res. 2012 Aug;22(8):1227-45. doi: 10.1038/cr.2012.82. Epub 2012 May 22.

PMID:
22613949
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

Cohn AL, Shumaker GC, Khandelwal P, Smith DA, Neubauer MA, Mehta N, Richards D, Watkins DL, Zhang K, Yassine MR.

Clin Colorectal Cancer. 2011 Sep;10(3):171-7. doi: 10.1016/j.clcc.2011.03.022. Epub 2011 Apr 28.

PMID:
21855038
[PubMed - indexed for MEDLINE]
18.

Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis.

Steinestel K, Brüderlein S, Steinestel J, Märkl B, Schwerer MJ, Arndt A, Kraft K, Pröpper C, Möller P.

PLoS One. 2012;7(7):e40671. doi: 10.1371/journal.pone.0040671. Epub 2012 Jul 10.

PMID:
22808230
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.

Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M, Chauffert B.

Cancer Chemother Pharmacol. 2002 Jun;49(6):445-52. Epub 2002 Apr 20.

PMID:
12107548
[PubMed - indexed for MEDLINE]
20.

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.

J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.

PMID:
23015072
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk